About this item:

146 Views | 62 Downloads

Author Notes:

Correspondence: Laureate Institute for Brain Research, 6655 S Yale Ave, Tulsa, OK 74136-3326, USA. hekhtiari@laureateinstitute.org (H. Ekhtiari)

Disclosures: Flavio Frohlich is the founder, majority owner, and Chief Scientific Officer of Pulvinar Neuro LLC. Michael Nitsche is a member of the Scientific Advisory Board of Neuroelectrics. Colleen A. Hanlon has served as a consultant for Brain Research and Development Services (Brainsway). Other authors reported no conflict of interest.

Subjects:

Research Funding:

Xavier Noël is supported by a grant of the Belgian Fund for Scientific Research (grant PDR/OL T.0146.18).

Anna E. Goudriaan and Renée S. Schluter are funded by an innovative VIDI grant awarded to AG (grant number 91713354) by the Netherlands Health Research Organization (ZonMW).

Elliot Stein and Vaughn Steele are supported by the Intramural Research Program of the National Institute on Drug Abuse (NIDA), National Institutes of Health, Baltimore, Maryland and The Center on Compulsive Behavior. Antonio Verdejo-García is supported by Australian Medical Research Future Fund (MRF1141214).

Laurie Zawertailo received funding from Canadian Institutes of Health Research, Canadian Cancer Society, Ontario Ministry of Health, and Global Research Awards in Nicotine Dependence. Flavio Frohlich received funding from NIH, Bran and Behavior Research Foundation, Human Frontiers Science Program, Tal Medical, and the Neurocare Group.

Shirley Fecteau is supported by the Canada Research Chair in Cognitive Neuroplasticity. Stacey Daughters is supported by the NIH/NIDA (R01DA026424).

Michael A. Nitsche receives funding from the German Research Foundation (DFG; SFB 1280 Project A6), and the German Federal Ministry of Education and Research (BMBF, GCBS grant 01EE1403C).

Coleen A. Hanlon received funding from the NIDA (R01DA04447) and NIAAA (P50AA010761).

Vincent Van Waes is supported by the Fondation pour la Recherche en Alcoologie (FRA) and the Région Bourgogne Franche-Comté.

Ganesan Venkatasubramanian is supported by the Swarnajayanti Fellowship Grant (DST/SJF/LSA-02/2014–15) by the Department of Science and Technology, Government of India.

Michael J. Wesley receives funding from the NIDA (K01DA043652; R01DA045023 and R01DA047368).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Behavioral Sciences
  • Neurosciences
  • Neurosciences & Neurology
  • Substance use disorder
  • Addiction
  • Non-invasive brain stimulation
  • Transcranial electrical stimulation
  • Transcranial magnetic stimulation
  • rTMS
  • tDCS
  • tES
  • NIBS
  • Psychiatry
  • Dorsolateral prefrontal cortex
  • Noninvasive brain stimulation
  • Theta burst stimulation
  • Alcohol dependent moments
  • Human motor cortex
  • Major depressive disorder
  • Substance use disorder
  • Compulsive drug use
  • Go-Nogo task
  • Functional connectivity

Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead

Tools:

Journal Title:

Neuroscience and Biobehavioral Review

Volume:

Volume 104

Publisher:

, Pages 118-140

Type of Work:

Article | Post-print: After Peer Review

Abstract:

There is growing interest in non-invasive brain stimulation (NIBS) as a novel treatment option for substance-use disorders (SUDs). Recent momentum stems from a foundation of preclinical neuroscience demonstrating links between neural circuits and drug consuming behavior, as well as recent FDA-approval of NIBS treatments for mental health disorders that share overlapping pathology with SUDs. As with any emerging field, enthusiasm must be tempered by reason; lessons learned from the past should be prudently applied to future therapies. Here, an international ensemble of experts provides an overview of the state of transcranial-electrical (tES) and transcranial-magnetic (TMS) stimulation applied in SUDs. This consensus paper provides a systematic literature review on published data – emphasizing the heterogeneity of methods and outcome measures while suggesting strategies to help bridge knowledge gaps. The goal of this effort is to provide the community with guidelines for best practices in tES/TMS SUD research. We hope this will accelerate the speed at which the community translates basic neuroscience into advanced neuromodulation tools for clinical practice in addiction medicine.

Copyright information:

© 2019 Elsevier Ltd. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Export to EndNote